NRXP
NRX Pharmaceuticals, Inc.
Overview
NRx Pharmaceuticals develops novel therapeutics for central nervous system disorders including suicidal depression, PTSD, chronic pain, and schizophrenia. The company's lead candidates—NRX-100 and KETAFREE (preservative-free ketamine formulations) and NRX-101 (an oral combination of D-cycloserine and lurasidone)—are in FDA review for approval.
NRX Pharmaceuticals, Inc is a Healthcare company operating in Biotechnology with a $169.9M market cap.
NRXP beat consensus EPS by 0.6% in Q1 FY2026, reported May 17, 2026.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
History
Earnings history
- Q1 FY20262026-05-17EPS$-0.04 vs $-0.11+59.6%Rev$1.1M vs ——EODHD
- Q4 FY20252026-03-23EPS$0.18 vs $-0.08+100.0%Rev$983.0K vs ——EODHD
- Q3 FY20252025-11-13EPS$-0.27 vs $-0.52+48.1%Rev$242.0K vs ——EODHD
- Q2 FY20252025-08-17EPS$-0.98 vs $-0.53-84.9%Rev$0 vs ——EODHD
- Q1 FY20252025-05-14EPS$-0.34 vs $-0.53+35.9%Rev$4.0K vs ——EODHD
- Q4 FY20242025-03-25EPS$-0.77 vs $-0.37-100.0%Rev$4.0K vs ——EODHD
- Q3 FY20242024-11-10EPS$-0.15 vs $-0.64+76.6%Rev$0 vs ——EODHD
- Q2 FY20242024-08-13EPS$-0.67 vs $-0.69+2.9%Rev$0 vs ——EODHD
- Q1 FY20242024-05-13EPS$-0.74 vs $-0.55-34.5%Rev$8.0K vs ——EODHD
- Q4 FY20232024-03-28EPS$-0.50 vs $-0.70+28.6%Rev$8.0K vs ——EODHD
- Q3 FY20232023-11-12EPS$-0.07 vs $-0.11+36.4%Rev$0 vs ——EODHD
- Q2 FY20232023-08-13EPS$-0.12 vs $-0.14+14.3%Rev$0 vs ——EODHD
- Q1 FY20232023-05-14EPS$-0.16 vs $-0.14-14.3%Rev$0 vs ——EODHD
- Q4 FY20222023-03-30EPS$-0.16 vs $-0.14-14.3%Rev$0 vs ——EODHD
- Q3 FY20222022-11-13EPS$-0.14 vs $-0.140.0%Rev$0 vs ——EODHD
- Q2 FY20222022-08-14EPS$-0.11 vs $-0.10-10.0%Rev$0 vs ——EODHD
- Q1 FY20222022-05-15EPS$-0.21 vs ——Rev$0 vs ——EODHD
- Q4 FY20212022-03-30EPS$-0.53 vs ——Rev$0 vs ——EODHD
- Q3 FY20212021-11-14EPS$-0.40 vs ——Rev$0 vs ——EODHD
- Q2 FY20212021-08-15EPS$-6.51 vs $0.00—Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-17 | $-0.04 | $-0.11 | +59.6% | $1.1M | — | — | EODHD |
| Q4 FY2025 | 2026-03-23 | $0.18 | $-0.08 | +100.0% | $983.0K | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-0.27 | $-0.52 | +48.1% | $242.0K | — | — | EODHD |
| Q2 FY2025 | 2025-08-17 | $-0.98 | $-0.53 | -84.9% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.34 | $-0.53 | +35.9% | $4.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-25 | $-0.77 | $-0.37 | -100.0% | $4.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-10 | $-0.15 | $-0.64 | +76.6% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-0.67 | $-0.69 | +2.9% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-13 | $-0.74 | $-0.55 | -34.5% | $8.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-28 | $-0.50 | $-0.70 | +28.6% | $8.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.07 | $-0.11 | +36.4% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.12 | $-0.14 | +14.3% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.16 | $-0.14 | -14.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-0.16 | $-0.14 | -14.3% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-0.14 | $-0.14 | 0.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-0.11 | $-0.10 | -10.0% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.21 | — | — | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.53 | — | — | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-0.40 | — | — | $0 | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-6.51 | $0.00 | — | $0 | — | — | EODHD |
Source: EODHD. NRXP reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks NRXP's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.74 | $2.74 | +0.1% | +0.6% | +2.3% |
| Q4 FY2026 | $2.98 | $2.84 | +4.8% | +3.0% | +0.4% |
| Q3 FY2026 | $3.05 | $2.81 | +8.5% | -7.1% | -7.8% |
| Q2 FY2026 | $2.80 | $2.79 | +0.4% | +2.2% | +4.9% |
| Q1 FY2025 | $2.94 | $2.79 | +5.4% | +3.3% | +4.2% |
| Q4 FY2025 | $2.87 | $2.80 | +2.4% | -4.8% | -2.4% |
| Q3 FY2025 | $3.02 | $3.05 | -1.1% | -3.3% | -1.1% |
| Q2 FY2025 | $3.13 | $2.88 | +8.6% | +0.2% | -1.7% |
| Q1 FY2024 | $2.96 | $3.00 | -1.3% | -2.7% | -5.5% |
| Q4 FY2024 | $3.39 | $3.00 | +13.1% | -6.7% | -4.8% |
Guidance change history
Sample- Q1 FY2026Maintained2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Maintained2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Maintained2025-13-15
- Q3 FY2025Suspended2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Joseph Michael CasperCOO5 mono recorded callsCurrentSample
COO since 2026 • 1/2 beats (50%) • guidance suspended Q2 FY2026
- Stephen H WillardCEO0 mo9 callsFormerSample
CEO since 2022 • 10/16 beats (63%) • guidance suspended Q3 FY2026
- Michael S AbramsCFO3 mo7 callsFormerSample
CFO since 2024 • 4/8 beats (50%) • last guidance raise Q2 FY2026
- Richard Clavano NaridoCFO0 mono recorded callsFormerSample
CFO since 2023 • 9/12 beats (75%) • last guidance cut Q2 FY2026
- Voorhees Seth VanCFO1 mono recorded callsFormerSample
CFO since 2022 • 9/16 beats (56%) • guidance suspended Q1 FY2026
- Ira S StrassbergCFO0 mo2 callsFormerSample
CFO since 2022 • 8/16 beats (50%) • last guidance raise Q3 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for NRXP.
$ curl https://api.spokenalpha.com/v1/companies/NRXPFAQ
Frequently asked about NRXP
Where can I find NRX Pharmaceuticals, Inc.'s (NRXP) earnings call transcripts?
Spoken Alpha indexes NRXP's earnings call transcripts at https://spokenalpha.com/companies/NRXP. Each call links to attributed speakers and parsed analyst Q&A. NRX Pharmaceuticals, Inc.'s own investor relations page is at https://ir.nrxpharma.com/.
What sector is NRXP in?
NRX Pharmaceuticals, Inc. (NRXP) operates in the Healthcare sector (Biotechnology industry).